Our Focus

Inotek is focused on bringing potentially sight-saving therapies to patients at risk.

Our most advanced product candidate, trabodenoson, is being developed both as a monotherapy and as a fixed-dose combination with latanoprost, a leading glaucoma treatment. We are also investigating the potential for trabodenoson to directly protect retinal ganglion cells from damage, aiding in the fight against vision loss.

 

Trabodenoson is an investigational compound and is not yet approved by the FDA.